Login to Your Account



Other News To Note


Tuesday, July 10, 2012
• Cangene Corp., of Winnipeg, Manitoba, granted Camurus AB, of Lund, Sweden, exclusive U.S. commercialization rights for episil in managing pain associated with oral lesions, including oral mucositis, resulting from cancer therapy and other causes. Financial terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription